Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
2.

Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A.

J Nucl Med. 2005 Oct;46(10):1625-32.

3.

Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.

Mosconi L, Herholz K, Prohovnik I, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Sorbi S, Pupi A.

J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):15-23.

4.

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.

de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H.

Ann N Y Acad Sci. 2007 Feb;1097:114-45. Review.

PMID:
17413016
5.

Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.

Vanitallie TB.

Metabolism. 2013 Jan;62 Suppl 1:S30-3. doi: 10.1016/j.metabol.2012.08.024. Epub 2012 Sep 26. Review.

PMID:
23021038
6.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
7.

Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease.

Dukart J, Kherif F, Mueller K, Adaszewski S, Schroeter ML, Frackowiak RS, Draganski B; Alzheimer's Disease Neuroimaging Initiative.

PLoS Comput Biol. 2013 Apr;9(4):e1002987. doi: 10.1371/journal.pcbi.1002987. Epub 2013 Apr 4.

8.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease.

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20. Review.

9.
10.

Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.

Small GW.

J Clin Psychiatry. 1996;57 Suppl 14:9-13. Review.

PMID:
9024331
11.

Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study.

Mosconi L, Sorbi S, Nacmias B, De Cristofaro MT, Fayyaz M, Bracco L, Herholz K, Pupi A.

Psychiatry Res. 2004 Feb 15;130(2):141-51.

PMID:
15033184
12.

Early diagnosis of Alzheimer dementia based on clinical and biological factors.

Almkvist O, Winblad B.

Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:3-9. Review.

PMID:
10654093
13.

Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.

Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G.

J Nutr Health Aging. 2008 Jan;12(1):61S-5S.

PMID:
18165848
14.

Association between GAB2 haplotype and higher glucose metabolism in Alzheimer's disease-affected brain regions in cognitively normal APOEε4 carriers.

Liang WS, Chen K, Lee W, Sidhar K, Corneveaux JJ, Allen AN, Myers A, Villa S, Meechoovet B, Pruzin J, Bandy D, Fleisher AS, Langbaum JB, Huentelman MJ, Jensen K, Dunckley T, Caselli RJ, Kaib S, Reiman EM.

Neuroimage. 2011 Feb 1;54(3):1896-902. doi: 10.1016/j.neuroimage.2010.09.066. Epub 2010 Oct 1. Erratum in: Neuroimage. 2011 Oct 1;58(3):974.

15.

The relation of regional cerebral perfusion and atrophy in mild cognitive impairment (MCI) and early Alzheimer's dementia.

Luckhaus C, Cohnen M, Flüss MO, Jänner M, Grass-Kapanke B, Teipel SJ, Grothe M, Hampel H, Peters O, Kornhuber J, Maier W, Supprian T, Gaebel W, Mödder U, Wittsack HJ.

Psychiatry Res. 2010 Jul 30;183(1):44-51. doi: 10.1016/j.pscychresns.2010.04.003. Epub 2010 Jun 11.

PMID:
20541374
16.

Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: a multicentric study.

Babiloni C, Benussi L, Binetti G, Bosco P, Busonero G, Cesaretti S, Dal Forno G, Del Percio C, Ferri R, Frisoni G, Ghidoni R, Rodriguez G, Squitti R, Rossini PM.

Neuroimage. 2006 Feb 1;29(3):948-64. Epub 2005 Oct 6.

PMID:
16213753
17.

Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions.

Reiman EM, Chen K, Caselli RJ, Alexander GE, Bandy D, Adamson JL, Lee W, Cannon A, Stephan EA, Stephan DA, Papassotiropoulos A.

Neuroimage. 2008 Apr 15;40(3):1214-21. doi: 10.1016/j.neuroimage.2007.12.066. Epub 2008 Jan 17.

18.

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71. Epub 2001 Aug 28.

19.

Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.

Chételat G, Fouquet M.

Rev Neurol (Paris). 2013 Oct;169(10):729-36. doi: 10.1016/j.neurol.2013.07.025. Epub 2013 Sep 6. Review.

20.

Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.

Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S.

Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review.

PMID:
19519314

Supplemental Content

Support Center